

Aims of Talk

- Discuss Preoperative Optimization
- Overview of the 5 preoperative interventions to actually effect improved surgical outcomes
- Hands on implementationexperience from an US Health System

Aim of Preoperative Assessment is to improve outcomes

Outcomes:

- Faster recovery
- Less complications
- Improved post operative function

Resulting in:

- Reduced Costs
- Positive return on up front investment of money and time

Aim of Preoperative Assessment is to improve outcomes

Outcomes:

- Faster recovery
- Less complications
- Improved post operative function

Resulting in:

- Reduced Costs
- Positive return on up front investment of money and time

Major Surgery is becoming increasingly recognized as a moment that Patients will change lifestyle to benefit their future health

5

Aim of Preoperative Assessment is to improve outcomes


Outcomes:

- Faster recovery
- Less complications
- Improved post operative function


Resulting in:


- Reduced Costs
- Positive return on up front investment of money and time

INFORMED DECISION MAKING


























	<u>NSQIP</u>	8	Sur Calc	gica cula	tor	sk		Carlor State	Inspir	ERICAN CO		
	Home	Abo	ut	FAQ		ACS	Websi	te		ACS NSQ	P Website	
	Procedure: 44156 - C Risk Factors: 75-84 yea disease. (Smoker, D		andent functio	nal status. E	mergent, AS	A Severe s	vstemic		-	Change Pat	ient Risk Facto	5
			Note: You	ır Risk has i	been round	d to one	decimal	point.				
	Readmission	10 20	30	40 5	0 60	70	80	90	100%	38.7%	9.9%	Above Average
	Return to OR	10 20	30	40 5	0 60	70	80	90	100%	15.3%	5.6%	Above Average
	Death	10 20	30	40 5	60	70	80	90	100%	55.0%	1.4%	Above Average
Discharge to Nu	ursing or Rehab Facility	10 20	30	40 5	0 60	70	80	90	100%	74.3%	6.5%	Above Average
	Sepsis	10 20	30	40 5	0 60	70	80	90	100%	0.0%	3.1%	Below Average
		Predic	ted Len	gth of H	lospital	Stay:	30 da	iys				
How to Inte Your Risk	Average Patient Risk	۷	our % Risk	they	feel the c	be use alculate increas	d infrec d risks ed risk	uently, are und s was l	but surg	eady entere	adjust the e should only	stimated risks if be done if the sk calculator.
<u>, , , , , , , , , , , , , , , , , , , </u>		Ва	ck	(Contin	ue					St	ep 3 of 4
	© 2007 - 2019, America	an College (of Surgeon	s Nationa	l Surgical	Quality	Improv	ement i	Progran	n. All Rights	Reservere	I.



Fleisher and Linde-Zwirble Perioperative Medicine 2014, 3:7 Perioperative http://www.perioperativemedicineiournal.com/content/3/1/7 Medicine RESEARCH **Open Access** Incidence, outcome, and attributable resource use associated with pulmonary and cardiac complications after major small and large bowel procedures Lee A Fleisher^{1*} and Walter T Linde-Zwirble² Results: Postoperative pulmonary complications (PPC) or postoperative cardiac complications (PCC) were present in 22% of cases; PPC alone was most common (19.0%), followed by PPC and PCC (1.8%) and PCC alone (1.2%). The incremental cost of PPC is large (\$25,498). In comparison, PCC alone only added \$7,307 to the total cost. Conclusions: The current study demonstrates that postoperative pulmonary complications represent a significant source of morbidity and incremental cost after major small intestinal and colon surgery and have greater incidence and costs than cardiac complications alone. Therefore, strategies to reduce the incidence of these complications should be targeted as means of improving health and bending the cost curve in health care. Post operative Pulmonary Complications – 19% Post operative Cardiac Complications – 1.2% Incremental Cost - \$25,498



Optimization Before Surgery

Element	Parameters
Glycemic Management	Target blood glucose level – 140 – 180 Treat with insulin – 200+, attending review
Anemia	Hb > 13 \rightarrow proceed to surgery Hb 10 - 12.9 \rightarrow consider IV iron before surgery Hb 7 - 10 \rightarrow IV iron infusion clinic, attending review Hb <7 \rightarrow Notify surgeon, IV iron clinic, consider transfusion, attending review
Smoking and alcohol cessation/ reduction	Decrease usage prior to surgery; ideally, quit at least 4 weeks prior to surgery. Smoking: messurg compliance with Octinine test if needed, consider inhaled steroids Refer to pulmonary clinic for respiratory function test
Incentive spirometry	Train patient on use Send patient home with incentive spirometer
Nutrition	If indicated, prescribe 5 days of immunonutrition
BMI	BMI > 40, STOP-BANG score and refer to attending
Carbohydrate loading	800 mL night before surgery 400 mL morning of surgery
Exercise	Give patient "Fit 4 Surgery" materials
Patient Education	Give patient "Smart 4 Surgery" materials and patient diary
Chronic Pain	If opioid intake exceeds 50 ME (morphine equivalents) refer to Chronic Pain Clinic
Discharge planning	Identify discharge location (SNF, etc.) and post- discharge support needs
Decolonization	Give decolonization kit (includes skin, oral and nasal) and instructions


The Big Five


- 1. Anemia
- 2. Glycemic Management
- 3. Nutrition/ Hydration / Carbohydrate Loading
- 4. Pulmonary
- 5. Chronic pain
- Hard stops
- Interventions

CHANGE OUTCOMES

OVCUHealth PACE (Preoperative) Clinic

ELEMENT	OPTIMIZATION / OUTPUT	
Glycemic Management	Target blood glucose level – 140 – 180 Treat with insulin – 200+, attending review	
Anemia	Hb > 13 → proceed to surgery Hb 10 – 12.9 → consider IV iron before surgery Hb 7 – 10 → IV iron infusion clinic, attending review Hb <7 → Notify surgeon, IV iron clinic, consider transfusion, attending review	
Smoking and alcohol cessation/ reduction	Decrease usage prior to surgery; ideally, quit at least 4 weeks prior to surgery Smoking - measure compliance with Cotinine test if needed, consider inhaled steroids Refer to pulmoary clinic for respiratory function test Aim for abstinence from alcohol for >2 weeks	PACE Staff
Incentive spirometry	Train patient on use Send patient home with incentive spirometer	
Nutrition	If indicated, prescribe 5 days of immunonutrition	
BMI	BMI > 40, STOP-BANG score and refer to attending	S ALL ALL
Carbohydrate loading	800 mL night before surgery 400 mL morning of surgery	
Exercise	Give patient "Fit 4 Surgery" materials	
Patient Education	Give patient "Smart 4 Surgery" materials and patient diary	
Chronic Opioid Use	If opioid intake exceeds 50 ME (morphine equivalents) refer to Chronic Pain Clinic	QI Implementation team Clinical Effectiveness
Decolonization	Give decolonization kit (includes skin, oral and nasal) and instructions for appropriate operations	
Discharge planning	Identify discharge location (SNF, etc.) and post-discharge support needs Frailty Score if appropriate	






Anticoagulants / Antiplatelets

ANTICOAGULANT	Minimum time between last dose of anticoagulant & spinal injection or catheter placement * longer in CRI/AKI	Use of Antithrombotic Agents in Patients with Indwelling Neurasial Catheters	Minimum time between spinal injection or cathel removal & next do of anticoagulant		
TRADITIONAL ANTICOAGULA					
Warfarin	Hold for 4 -5 days when INR < 1.5	CONTRAINDICATED	2 hours		
Heparin full dose IV	when aPTT < 40. Check after holding 2 hours				
Heparin minidose (5000 Units) SQ BID	No contraindication	Indwelling catheter OK	Thour		
Heparin minidose (5000 Units) SQ TID	when aPTT < 40 or 6 hous after last dose	 Indwelling catheter OK 	Thour		
Neparin full dose (>5000 Units) SQ bid or TID	when aPTT < 40 or 6 hours after last dose	1			
Fondaparinux (Arixtra) <2.5mg SQ qd	36-42 hours		6-12 hours		
Fondaparinux (Aristra) 5-10mg SQ qd	Contraindicated	CONTRAINDICATED			
Enexaparin (Lovenox) Full dose 1mg/kg SQ bid; 1.5mg/kg SQ qd	24 hours*		24 hours		
Enexaparin (Lovenex) Prophylaxis 40mg SQ qd	12 hours*		6-8 hours		
DIRECT THROMBIN INHIBITO	RS				
Argatroban Bivalirudin (Angiomax)	unknown orwhen DTI assay < 40 or aPTT < 40	CONTRAINDICATED	unknown		
Lepirudin (Refludan)					
		write catheter in place			
ORAL ANTIPLATELET AGENT		given. No time restrictions			
ORAL ANTIPLATELET AGENT Aspirin/NSA/DS Clopidogrei (Pfavik) Prasugrei (Effient)	May be 7 days		2 hours		
ORAL ANTIPLATELET AGENT Aspirin/NSADS Clepidogrei (Plavik) Prasugrei (Effent) Ticlopidine (Ticlid)	May be	given, No time restrictions	2 hours		
ORAL ANTIPLATELET AGENT Aspirin/NSAIDS Clepislogrei (Plavis) Prasugrei (Britient) Ticlopidion: (Ticlid) GP IIB / IIIA INHIBITORS	May be 7 days 14 days	given, No time restrictions	2 hours		
ORAL ANTIPLATELET AGENT Asprin:NSADS Ciepidograf (Plavis) Prasugraf (Brient) Ticlosidine: fTiclid) GP IIB / IIIA INHIBITORS Kastemab (Reopro)	7 days 14 days 48 hours	given, No time restrictions			
ORAL ANTIPLATELET AGENT AsprinnNEADS (Expendingers (Bravis) Prassugers (Britent) Ticlosoidine (Ticlid) GP IIB / IIIA INHIBITORS Abstismab (Recyro) Eptifibatide (Unegrafin)	All May be 7 days 14 days 48 hours 8 hours	given, No time restrictions CONTRAINDICATED while catheter in place	2 hours 2 hours		
ORAL ANTIPLATELET AGENT Aspirin/NSA05 (Epishogref (Plavis) Prasuget (Effent) Tubender (Tibel) GP IIB / IIIA INHIBITORS Abstimme (Respre) Episihautise (Integritin) Turefitan (Ageneta)	7 days 14 days 48 hours	CONTRAINDICATED			
ORAL ANTIPLATELET AGENT AsprinnNEADS (Expendingers (Bravis) Prassugers (Britent) Ticlosoidine (Ticlid) GP IIB / IIIA INHIBITORS Abstismab (Recyro) Eptifibatide (Unegrafin)	All May be 7 days 14 days 48 hours 8 hours	CONTRAINDICATED			
ORAL ANTIPLATELET AGENT AspirinvRAD3 Cicplefogrei (Pavis) Prasuget (Effient) Ticloadier (Ticlia) OP IIB / IIIA INHIBITORS Attochmab (Regress) Explosited (Regress) Terriften (Regress)	May be 7 days 54 days 48 hours 8 hours 8 hours 9 hours 10 days	Sues, No time restrictions CONTRANDICATED while catheter in place CONTRANDICATED while catheter in place CONTRANDICATED	2 hours 10 days		
ORAL ANTIPLATELET AGENT Apprix/MEX/05 Scheholiger (Inven) Tislendinger (Inven) Tislendinger (Inven) Op 105 / 108 ANTIBITORS Adaptionalist (Recycr) Experimentation (Invention Terroffband (Ageneration) Terroffband (Ageneration) Terroffband (Ageneration) Terroffband (Invention) Terroffband (Invention) Terroffband (Invention) Adaptates (IPA) Full does for stroke, MI Adaptates (IPA) Full does for stroke, MI	May be 7 days 7 days 14 daws 48 hours 8 hours 10 days 10 days 10 days	CONTRANDICATED CONTRANDICATED while definite in place antie contexter in place while contexter in place CONTRANDICATED while contexter in place	2 hours 10 days		
ORAL ANTIPLATELET AGENT Augustum (KARDS Markensen) Tallagedinen) Tallagedinen) Tallagedinen (Talla) Alasianaka (TRA) (Trained (Trained Tellar) (Alagense) THROMOLITIC AGENTS Alagelase (TPA) (Train does for etobes, NI Alagelase (TPA) (Train does for eather etobes, Trained (TPA)	May be 7 days 7 days 14 daws 48 hours 8 hours 10 days 10 days 10 days	CONTRANDICATED CONTRANDICATED while definite in place antie contexter in place while contexter in place CONTRANDICATED while contexter in place	2 hours 10 days		
ORAL ANTIPLATELET AGENT Augustraktions Processor (Bene) Totopation (Tiella) Or III J. IIII A. INHIBITORS Alacimak (Resport) Difficialitie (Integration) Terrifican (Degrated) Terrifican (Degrated) Antiplase (TPA) Jimi does for actives, NI Antiplase (TPA) Jimi does for actives, NI Antiplase (TPA) Jimi does for actives (Desratives)	May be r 7 days 14 days 48 hours 8 hours 9 hours 10 days May be given, No time 5	CONTRACTOR AND CONTRACTOR AN	2 hours 10 days		

Adjust / stop at appropriate time for:

- Type of surgery
- If regional anesthesia
- Can be complicated in patients with Drug eluting stents
- Often need to discuss with primary cardiologist / physician





American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Nutrition Screening and Therapy Within a Surgical Enhanced Recovery Pathway

Paul E. Wischmeyer, MD, EDIC,* Franco Carli, MD, MPhil,† David C. Evans, MD, FACS,‡ Sarah Guilbert, RD, LDN, CNSC,§ Rosemary Kozar, MD, PhD,∥ Aurora Pryor, MD, FACS,¶ Robert H. Thiele, MD,# Sotiria Everett, EdD, RD,** Mike Grocott, BSc, MBBS, MD, FRCA, FRCP, FFICM,††‡‡§§III Tong J. Gan, MD, MHS, FRCA,¶¶ Andrew D. Shaw, MB, FRCA, FCCM, FFICM,##*** Julie K. M. Thacker, MD,†† and Timothy E. Miller, MB, ChB, FRCA,‡‡‡ for the Perioperative Quality Initiative (POQI) 2 Workgroup




June 2018 • Volume 126 • Number 6








Perioperative Use of Arginine-supplemented Diets: A Systematic Review of the Evidence

John W Drover, MD, FRCSC, Rupinder Dhaliwal, RD, Lindsay Weitzel, PhD, Paul E Wischmeyer, MD, Juan B Ochoa, MD, FACS, Daren K Heyland, MD, FRCPC, MSC









EXECTENSIÓN BRECOMMENDADADE A Commendation of the preoperative o



Recommendations - 3

- In patients undergoing surgery who are considered to have minimal specific risk of aspiration, we encourage unrestricted access to solids for up to 8 h before anesthesia and clear fluids for oral intake up to 2 h before the induction of anesthesia.
- We recommend a preoperative carbohydrate drink containing at least 45 g of carbohydrate to improve insulin sensitivity (except in type I diabetics due to their insulin deficiency state). We suggest that complex carbohydrate (eg, maltodextrin) be used when available


33

PULMONARY

Pulmonary Optimization

- Incentive Spirometry for all
- Inspiratory muscle training
- COPD optimization
- Antibiotics / Steroids in severe chest disease
- Operate when weather good!







REVIEW ARTICLE


Inspiratory muscle training is effective to reduce postoperative pulmonary complications and length of hospital stay: a systematic review and meta-analysis


Filipa Kendall^{a,b,c}, José Oliveira^c, Bárbara Peleteiro^{d,e}, Paulo Pinho^a and Pedro Teixeira Bastos^a

^aDepartment of Cardiothoracic Surgery, Centro Hospitalar de São João, Porto, Portugal; ^bPolytechnic Health Institute of the North, CESPU, Gandra, Paredes, Portugal; 'Research Center in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, Porto, Portugal; 'dePlUnit – Institute of Public Health, University of Porto, Porto, Portugal; "Department of Clinical Epidemiology, Predictive Medicine and Public Health, Faculty of Medicine, University of Porto, Porto, Portugal

DISABILITY AND REHABILITATION, 2017

http://dx.doi.org/10.1080/09638288.2016.1277396






Inspiratory Muscle Training – Reduction in Pulmonary Complications

	11	мт	Cor	itrol														
Study	PPC	Total	PPC	Total	RR [95% CI]	Weight (%)											
Weiner, 1997 [24]	5	17	6	15	0.74 [0.28, 1.93]	5.09				_	i.		_					
Weiner, 1998 [3]	1	42	3	42	0.33 [0.04, 3.08]	2.39		_			-							
Hulzebos, 2006 [25]	25	139	48	137	0.51 [0.34, 0.78]	38.57				-	ż	-						
Hulzebos, 2006 [26]	3	14	7	12	0.37 [0.12, 1.12]	6.01			-	_	Ŧ	4						
Dronkers, 2008 [6]	3	10	8	10	0.38 [0.14, 1.02]	6.38			-		+	4						
Ferreira, 2009 [27]	2	15	0	15	5.00 [0.26, 96.13]	0.40				_	+	+						-
Dronkers, 2010 [31]	5	22	5	20	0.91 [0.31, 2.68]	4.18				_	+	+	_					
Kulkarni, 2010 [19]	0	18	2	19	0,21 [0,01, 4,11]	1.94					÷	+		_				
Benzo, 2011 [22]	3	10	6	9	0.45 [0,16, 1,29]	5.04					4	+						
Matheus, 2012 [30]	9	23	19	24	0.49 [0.29, 0.86]	14.84				_	٠	-						
Morano, 2013 [23]	2	12	7	9	0.21 [0.06, 0.80]	6.38		-			÷	-						
Soares, 2013 [32]	5	16	11	16	0.45 [0,20, 1,01]	8.78				_	+	-						
Overall	63	338	122	328	0.5 [0,39, 0,64]	100				1	φ							
Heterogeneity: I ² = 0.0%	; p=0.807									-	+	_	-		-	-,-		
							.01 .02	.05 MT re	.1 duces	.2 PPC	.5	1	2	5 IMT in	10 creas	20 es PPC	50	100


REVIEW ARTICLE	
	effective to reduce postoperative pulmonary hospital stay: a systematic review and meta-analysis
Filipa Kendall ^{a,b,c} , José Oliveira ^c , Bárbara	Peleteiro ^{d,e} , Paulo Pinho ^a and Pedro Teixeira Bastos ^a
Gandra, Paredes, Portugal; CResearch Center in Phy	spitalar de São João, Porto, Portugal; ^b Polytechnic Health Institute of the North, CESPU, sical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, Porto, versity of Porto, Porto, Portugal; "Department of Clinical Epidemiology, Predictive Medicine of Porto, Porto, Portugal
	DISABILITY AND REHABILITATION, 2017
	http://dx.doi.org/10.1080/09638288.2016.1277396
tive pulmonary complications (PPC) start preoperatively. Rehabilitation with IMT is beneficial more, as well as pulmonary surgery IMT is more effective if it is superv	vised, and prescription target at least two-week period, sessions
with more than 15 minutes, with imp	posed load increment, and adding other exercise modes.





GLYCEMIC MANAGEMENT


Perioperative Glucose Control

- Patients affected by diabetes have longer hospital stays
- Poorly controlled diabetes and hyperglycemia in hospitalized patients is associated with poor outcomes: cardiac and non-cardiac surgery, acute MI, pneumonia, subarachnoid hemorrhage, blunt injury and transplant
- Hyperglycemia without a diagnosis of diabetes is commonly untreated or undertreated in the hospital setting
- Acute illness, inconsistent caloric intake, changes from home medications, and limitations regarding the timing of glucose monitoring and insulin administration are all significant obstacles to managing inpatient hyperglycemia.
- The financial benefits of glycemic control are significant in reducing direct hospital costs by reducing length of stay and in decreasing readmission rates









CHRONIC OPIOID USERS

Reducing Perioperative Opioid Use

JAMA Surgery | Original Investigation

New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults

Chad M. Brummett, MD; Jennifer F. Waljee, MD, MPH, MS; Jenna Goesling, PhD; Stephanie Moser, PhD; Paul Lin, MS; Michael J. Englesbe, MD; Amy S. B. Bohnert, PhD, MHS; Sachin Kheterpal, MD, MBA; Brahmaiee K. Nallamothu. MD, MPH


> JAMA Surg. doi:10.1001/jamasurg.2017.0504 Published online April 12, 2017.


- Opioid addiction after surgery 5.9%-6.5%
- Minor as well as major surgery
- Behavioral and Pain disorders are a risk factor
- Opioid addiction is now the commonest major complication after surgery



RESULTS A total of 36 177 patients met the inclusion criteria, with 29 068 (80.3%) receiving minor surgical procedures and 7109 (19.7%) receiving major procedures. The cohort had a mean (SD) age of 44.6 (11.9) years and was predominately female (23 913 [66.1%]) and white (26 091 [72.1%]). The rates of new persistent opioid use were similar between the 2 groups, ranging from 5.9% to 6.5%. By comparison, the incidence in the nonoperative control cohort was only 0.4%. Risk factors independently associated with new persistent opioid use included preoperative tobacco use (adjusted odds ratio [0.08], 1.35; 95% C1, 1.21-49), alcohol and substance abuse disorders (a0R, 1.34; 95% C1, 105-1.72), mood disorders (a0R, 1.15; 95% C1, 101-1.30), anxiety (a0R, 1.25; 95% C1, 1.10-1.42), and preoperative pain disorders (back pain: a0R, 1.57; 95% C1, 1.42-1.75; neck pain: a0R, 1.32; 95% C1, 1.26-1.54).

CONCLUSIONS AND RELEVANCE New persistent opioid use after surgery is common and is not significantly different between minor and major surgical procedures but rather associated with behavioral and pain disorders. This suggests its use is not due to surgical pain but addressable patient-level predictors. New persistent opioid use represents a common but previously underappreciated surgical complication that warrants increased awareness.





Implementation

Liaise with Chronic Pain Have referral system in place Hard stops for elective surgery


Choose a MME dose (we choose 60) = morphine equivalents per day Aim to reduce use prior to surgery


Suboxone – different approach Aim to Half the dose before surgery, don't try and stop


Liase with Acute Pain Team so that on day of surgery: Neuroxial and truncal block are used Ketamine, dexmeditomidine and lidocaine infusions can be used

53

PeriOperative Quality Improvement POQI Group: Analgesia within a Colorectal Surgery ERP









Anemia and Surgical Outcome

- 1. Data from large series now suggest that anemia is an independent risk associated with poor outcome in both cardiac and non-cardiac surgery.
- 2. Blood transfusion does not appear to ameliorate this risk, and in fact may increase the risk of postoperative complications and hospital length of stay.


Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. *Anesthesiology* 2010; 113: 482–95.


Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac sur- gery: a retrospective cohort study. *Lancet* 2011; 378: 1396–407.













Rationale - Why Optimize Preoperative Hb?

Anemia increases all cause risk for patients Anemia increases costs and resource allocation Blood transfusion does not fix this – downstream risks An optimal Perioperative pathway screens and optimizes Hb and iron stores prior to surgery

PREOPERATIVE SCREENING & OPTIMIZATION OF HEMOGLOBIN



Which Lab Tests and when?
CBC – look at all cell lines (to exclude hematological issue) Creat/ eGFR Ferritin
Fe
TIBC
TSAT
B12 / Folate
CRP
If Hb unknown - do we do them all in the first sitting? – or screen with a point of care test and then draw the labs after this?



Anemia of Chronic Disease - Why Oral Iron May Not Work

Chronic disease can cause a state of functional iron deficiency leading to anemia.

The key iron regulatory protein hepcidin is activated in response to inflammation and inhibits absorption of iron from the gastrointestinal tract and reduces bioavailability of iron stores for red cell production in the marrow.

Although iron stores (predominantly ferritin) may be normal, the transport of iron either from the gastrointestinal tract or iron stores to the bone marrow is inhibited, leading to a state of 'functional' iron deficiency and subsequent anemia.

Since absorption from the gastrointestinal tract is blocked, increasing oral iron intake is ineffective 2017, 72,233-247

Intravenous Iron

Replenishes iron stores and increases Hb in anemia due to iron deficiency with or without inflammation

Dosing may be calculated from the baseline and target Hb and patient's body weight, adding 500 mg for iron stores

Low incidence of reactions

1000–1500 mg is sufficient in most surgical patients

Given by slow infusion over less than 1 h in one sitting or in two – three divided doses over 2-3 weeks

Most patients feel better in 3 days with a rapid Hb response (50% at 5 days, 75% at 10–14 days, maximal at 3 weeks) Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. Journal of Clinical Pathology 2011; 64: 287–96 Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823–33

Calculating Iron Deficit	nteral dosing) for Iron < Share
Deficiency	
Input:	
Age Factor • Adult >= 33 lb (14.8)	Result:
○ Child < 33 lb (12)	Dose _2116 ^{mg}
Weight 180 © Ib 🗸	
Hgb 9 gm/dL 🗸	Decimal Precision: 2 V
Formula Notes Refere	ences
Dose = 0.3 * Weight * (100 - (Hg	ıb * 100) / AgeFactor)
69	

Calculating Iron Deficit									
Iron Replacement (pare Deficiency	nteral dosing) for Iron < Share								
Input:									
Age Factor • Adult >= 33 lb (14.8)	Result:								
○ Child < 33 lb (12)	Dose								
Weight 180 Ib 🗸									
Hgb 11 💿 gm/dL 🗸	Decimal Precision: 2 V								
Formula Notes Reference	nces								
Dose = 0.3 * Weight * (100 - (Hg	b * 100) / AgeFactor)								

Intravenous Iron

Replenishes iron stores and increases Hb in anemia due to iron deficiency with or without inflammation

Dosing may be calculated from the baseline and target Hb and patient's body weight, adding 500 mg for iron stores

Low incidence of reactions

1000–1500 mg is sufficient in most surgical patients

Given by slow infusion over less than 1 h in one sitting or in two – three divided doses over 2-3 weeks

Most patients feel better in 3 days with a rapid Hb response (50% at 5 days, 75% at 10–14 days, maximal at 3 weeks) Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. Journal of Clinical Pathology 2011; 64: 287–96 Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823–33

71

Intravenous Iron Preparations – Absoluteatales of infeator and Absolution Absolution and a second and a secon

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $									
$ \begin{array}{ccccc} Cardiac arrest & 3 & 8 & 5 & 0 & 4.2 (1.4+12) & 0.3 (0.1-1.3) & 0.0 (0.0-0.6) & 0.0 \\ Coma & 1 & 13 & 6 & 4 & 5.7 (2.2+14) & 0.1 (0.0-0.6) & 0.5 (0.2-1.7) & 5.0 (0.0-0.5) & 0.0 \\ Anaphylactoid reaction & 4 & 6 & 6 & 0 & 2.6 (0.9-7.7) & 0.4 (0.1-1.3) & 0.0 (0.0-0.5) & 0.0 \\ Dyspnea^{b} & 9 & 44 & 28 & 10 & 4.1 (2.6-6.5) & 0.2 (0.1-0.4) & 0.3 (0.1-0.5) & 0.0 \\ Altergic reaction^{b} & 23 & 22 & 25 & 18 & 2.4 (1.4+4.2) & 0.5 (0.3-0.9) & 0.5 (0.3-1.0) & 0.0 \\ Abdominal pain & 10 & 2 & 3 & 5 & 1.7 (0.3-8.7) & 1.8 (0.5-6.3) & 1.3 (0.3-4.8) & 0.0 \\ Back pain & 7 & 2.8 & 8 & 4 & 9.1 (4.2-20) & 0.5 (0.2-1.3) & 0.3 (0.1-0.9) & 0.0 \\ Hypotension & 20 & 2.8 & 16 & 9 & 5.2 (2.9-4.1) & 0.5 (0.3-0.9) & 0.0 & 0.0-9.9 & 0.0 \\ Hypotension & 20 & 2.8 & 10 & 10 & 2.1 (0.9-5.1) & 0.5 (0.2-1.2) & 0.8 (0.3-1.8) & 0.0 \\ Hypotension & 11 & 8 & 10 & 10 & 2.1 (0.9-5.1) & 0.5 (0.2-1.2) & 0.8 (0.3-1.8) & 0.0 \\ Sweating & 4 & 15 & 4 & 3 & 9.8 (3.4-28) & 0.4 (0.1-1.7) & 0.6 (0.1-2.3) & 1 \\ Total & 232 & 331 & 269 & 175 & 3.2 (2.7-3.8) & 0.4 (0.1-1.7) & 0.6 (0.1-2.3) & 1 \\ \end{array}$	ADE								OR Venofer vs Ferrlecit®
	Death	3	2	5	1	1.0 (0.2-4.6)	0.3 (0.1-1.3)	0.2 (0.1-1.0)	0.5 (0.1-3.2)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Cardiac arrest	3	8	5	0	4.2 (1.4-12)	0.3(0.1-1.3)	0.0 (0.0-0.6)	0.0 (0.0-1.7)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Coma	1	13	6	4	5.7 (2.2-14)	0.1 (0.0-0.6)	0.5(0.2-1.7)	5.4 (0.8-36)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Anaphylactoid reaction	4	6	6	0	2.6(0.9-7.7)	0.4(0.1-1.3)	0.0 (0.0-0.5)	0.0(0.0-1.3)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		9	44	28	10	4.1 (2.6-6.6)	0.2(0.1-0.4)	0.3(0.1-0.5)	0.9(0.3-2.4)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		23	22	25	18	2.4(1.4-4.2)	0.5(0.3-0.9)	0.5(0.3-1.0)	0.9(0.5-1.8)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		10	2	3	5	1.7 (0.3-8.7)		1.3 (0.3-4.8)	0.7 (0.2 - 1.9)
	Back pain	7	28	8	4	9.1 (4.2-20)	0.5(0.2-1.3)	0.3(0.1-1.0)	0.6(0.2-2.1)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		8	32	16	9	5.2 (2.9-9.4)	0.3 (0.1-0.6)	0.4(0.2-0.9)	1.5 (0.5-3.5)
Vomiting 13 6 7 3 2.4 (0.8-6.3) 1.0 (0.4-2.5) 0.3 (0.1-1.2) 0 Sweating 4 1.5 4 3 9.8 (3.4-2.8) 0.4 (0.1-1.7) 0.6 (0.1-2.3) 1 Total 232 331 269 175 3.2 (2.7-3.8) 0.5 (0.4-0.6) 0.5 (0.4-0.6) 0.4 (0.4-0.6)	Hypotension	20	26	12	12	5.7 (2.9-11)	0.9 (0.4-1.8)	0.8(0.3-1.7)	0.8 (0.4–1.6)
	Nausea	11	8	10	10	2.1(0.9-5.1)	0.5(0.2-1.2)	0.8(0.3-1.8)	1.5 (0.6-3.6)
Total 232 331 269 175 3.2 (2.7–3.8) 0.5 (0.4–0.6) 0.5 (0.4–0.6) 1	Vomiting	13	6	7	3	2.4(0.8-6.3)	1.0(0.4-2.5)	0.3(0.1-1.2)	0.3 (0.1-1.1)
Total 232 331 269 175 3.2 (2.7–3.8) 0.5 (0.4–0.6) 0.5 (0.4–0.6) 1		4	15	4	3				1.3 (0.3-5.9)
Life-threatening 11 29 22 5 3.4 (2.0–5.9) 0.3 (0.1–0.7) 0.2 (0.1–0.4) 0		232	331	269	175				1.0 (0.8-1.2)
	Life-threatening	11	29	22	5				0.6 (0.2-1.7)

The absolute rates of life-threatening ADEs were:


0.6 per million for Venofer,

0.9 per million for Ferrlecit,


3.3 per million for InFed


11.3 per million for Dexferrum

Search: Infusion	pe:
🟚 🖆 🚖 🕶 🖬 Folder: Search within: All	
a Medications	300 mg. Injectable. IV. once, Pharmacy to mix dose -100mg in 100ml. NaCl 0.9%; dose 100mg
🗷 Details for iron sucrose	
🖀 Details 📴 Order Comments 🕼 Offset Details 🗋 🐼 Diagnoses	
Order details 📫 📽 III.	Detail values
Dose [300]	300
Dose Unit [mg] Usage Guide	
Dosage Guide [Injectable]	
Route of Administration [IV] Frequency [once]	
PRN [No]	*
PRN Reason	
PRN Reason other Type in Special instructions	
Special Instructions Type-in [Pharmacy to mix]	
Duration Duration Unit	
Give first dose: [NOW]	
Requested Start Date/Time	
thetics	
Iidocaine-prilocaine topical (lidocaine-prilocaine	5 g, Cream, Topical, once, PRN Needle procedure, At intended site of IV access, Give first dose:
2.5%-2.5% topical)	May apply up to 5 g per procedure (up to 2.5 g x 2 sites if needed) to a MAX daily dose of 20 g.
ons	
Select appropriate order sentence(s) only if the patient has experienced reaction(s) w Use the following diphenhydrAMINE order for PO dosing:	vith previous administration(s) or the medication routinely causes infusion related reaction(s)
diphenhydrAMINE	Select an order sentence
Use the following diphenhydrAMINE order for IV dosing:	
🤣 🔯 diphenhydrAMINE	Select an order sentence
acetaminophen methylPREDNISolone	Select an order sentence Select an order sentence
tion	Select an order sentence
Select one appropriate order sentence for each medication in this section	
Use the following diphenhydrAMINE order for PO dosing:	



Cost Benefit of IV Iron versus Oral Iron Colorectal Surgery - Direct and indirect costs for acquisition and administration of iron product and RBC concentrates as well as hospitalization costs, were included in the cost model. Ferric carboxymaltose reduced hospital stay by 2.3 days Iron sucrose reduced hospital stay by 2.6 days (compared with oral iron) Cost savings of £ 437 (485€, \$532) and £ 245 (274€, \$300) per patient, respectively. Calvet X, Gene E, Ruiz MA, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technology and Health Care 2016; 24: 111–20.








What level of Hb is Threshold for Transfusion?

This effectively fixes your 'target preoperative Hb' in urgent cases Tolerate Hb 7.0 to 9.0 g/dl (ASA Guidelines) Individualized: Cardiac and Respiratory Patients – higher target ? Elderly should have higher target Rate of change of Hb – ie bleeding also a significant factor in giving blood However evidence supports maintaining HCT >28-30% to minimize complications

Which preoperative Hb target? 1. Elective Surgery – Hard stops for normal Hb 2. Urgent Surgery - individualize Work out blood volume on ideal body weight Work out predicted blood loss Work out likely nadir hematocrit for patient to get complications Calculate necessary starting Hb to not hit nadir hematocrit if average blood loss occurs Preoperative ongoing blood loss? How fast?







Anemia Clinic - Practical Tips

Run in conjunction with Preoperative Anesthesia Clinic – other optimization opportunities Screening – do not just rely on ferritin Fe; TIBC; TSAT all needed Need to exclude cause of anemia – cancer until proved otherwise Hematological and internal medicine 'buy in' Referral process for difficult diagnosis Oral supplements (Iron, Folate, B12)

83

Anemia Clinic - Practical Tips

Infusion clinic – set up powerplan for IV Iron Ideally 1 infusion but may need 2 or 3 ? Need to measure efficacy – CBC Liaise with Infusion Clinics who give chemotherapy – allows IV iron infusion to be given in satellite sites

Close liaison with surgeon for urgent cases or where blood loss is ongoing Expect around 1g per week rise in Hb Need to have a means of logging patients for iron therapy – virtual clinic Funding – Medicare v Insured

<text><text><text><text><text><text></text></text></text></text></text></text>		Martin Romany Martin	The main steps to stop yourself from getting a chest infection are: 3) Use your incentive spirometer as shown in the following video
OVCUI lealth.	PACE Chris	A transfer on indexisto number A transfer on indexisto n	Patient Video Education Room
	9		Dr Rachit Shah Thoracic & Esophageal Surgery
4			
		ה בפורה ביצורה	

What to tell the Surgeons

Optimization Timeline

Nutrition supplement	5 – 7 days minimum	5 days	Prescribed by PACE for patients at risk or who score
Opioid tolerance	7 – 14 days	Try to get patient to reduce opioid intake by 20%	Suboxone buprenorphine naltrexone all need specialist advice PACE will refer to Dr. Chapman at NOW; May be needed to reduce dependency and cut opioids by 20%. Adviced uce de email or clinic visit
Hb 10 – 12 IV iron infusions Follow PACE Anemia Algorithm	10 – 14 days Allows for 2 infusions	1 infusion as soon as logistically possible; more if timescale permits	Elective surgeries: End Stage Renal Failure needs EPO as well; PACE will refer to renal physician for action; unexplained anemia may need referral to Dr. Fang Urgent surgeries: continue IV iron infusion post- operatively
Hb 8 – <10 IV iron infusions Follow PACE Anemia Algorithm	14 – 21 days Allows for 2 – 3 infusions	1 infusion if possible; more if timescale permits	Urgent surgeries: Continue IV iron infusion post-operatively If Hb < 8 admit for blood transfusion (discussion between PACE and surgeon)
Exercise	7 days minimum 28 days ideal	Encourage up to day of surgery as tolerated	 Aerobic to target cardiopulmonary fitness. Resistance Exercise helpful. Diet important. Data shows 1 week provides improvement and a plateau after 4 weeks
Glycemic management			Elective surgeries: Ideal Hb A1c < 7.5 Urgent surgeries: If glucose is unstable, referif Hb A1c > 8 to endocrine team
Oral carbohydrate preload	1 day - Evening before and morning of surgery	1 day - Evening before and morning of surgery	



Summary

- 1. Enhanced Recovery after Surgery (ERAS) Pathways require preoperative assessment and optimization of modifiable risk factors
- 2. In the USA the most important of which are:
- Anemia
- Nutrition
- Glycemic control
- Chronic Opioid use
- Pulmonary

